JP5824055B2 - Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害剤 - Google Patents
Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害剤 Download PDFInfo
- Publication number
- JP5824055B2 JP5824055B2 JP2013530829A JP2013530829A JP5824055B2 JP 5824055 B2 JP5824055 B2 JP 5824055B2 JP 2013530829 A JP2013530829 A JP 2013530829A JP 2013530829 A JP2013530829 A JP 2013530829A JP 5824055 B2 JP5824055 B2 JP 5824055B2
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- indazole
- carbonyl
- spiro
- isopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *c1n[n](*)c2c1*C(CC1)(CCN1C(*I*C(O*)=O)=O)CC2=O Chemical compound *c1n[n](*)c2c1*C(CC1)(CCN1C(*I*C(O*)=O)=O)CC2=O 0.000 description 2
- VQRZNRIPXHCTOL-UHFFFAOYSA-N CC(C)(C)OC(CN(C)c1nc(OC)cc(C(O)=O)c1)=O Chemical compound CC(C)(C)OC(CN(C)c1nc(OC)cc(C(O)=O)c1)=O VQRZNRIPXHCTOL-UHFFFAOYSA-N 0.000 description 1
- UPNVJUTVKMEHNI-UHFFFAOYSA-N CC(C)(C)[n]1ncc(CC(CC2)(CCN2C(OCc2ccccc2)=O)C2Br)c1C2=O Chemical compound CC(C)(C)[n]1ncc(CC(CC2)(CCN2C(OCc2ccccc2)=O)C2Br)c1C2=O UPNVJUTVKMEHNI-UHFFFAOYSA-N 0.000 description 1
- CPQICQZWZUVUIY-UHFFFAOYSA-N CC(C)(C)[n]1ncc(CC(CC2)(CCN2C(c(cc2)ccc2OCc(cc2)ccc2C(OC)=O)=O)C2)c1C2=O Chemical compound CC(C)(C)[n]1ncc(CC(CC2)(CCN2C(c(cc2)ccc2OCc(cc2)ccc2C(OC)=O)=O)C2)c1C2=O CPQICQZWZUVUIY-UHFFFAOYSA-N 0.000 description 1
- YYQWGOFROFKXAZ-UHFFFAOYSA-N CC(C)(C)[n]1ncc(CC2(CCN(CC(c(cc3)ccc3OCc(cc3)ccc3C(O)=O)=O)CC2)C2)c1C2=O Chemical compound CC(C)(C)[n]1ncc(CC2(CCN(CC(c(cc3)ccc3OCc(cc3)ccc3C(O)=O)=O)CC2)C2)c1C2=O YYQWGOFROFKXAZ-UHFFFAOYSA-N 0.000 description 1
- RAGWEVGDRMMGPX-UHFFFAOYSA-N CC(C)[n](c1c2CC(CC3)(CCN3C(OCc3ccccc3)=O)CC1=O)nc2Br Chemical compound CC(C)[n](c1c2CC(CC3)(CCN3C(OCc3ccccc3)=O)CC1=O)nc2Br RAGWEVGDRMMGPX-UHFFFAOYSA-N 0.000 description 1
- UTQOAIWPJIFJIS-UHFFFAOYSA-N CC(C)[n](c1c2CC3(CCNCC3)CC1=O)nc2C#N Chemical compound CC(C)[n](c1c2CC3(CCNCC3)CC1=O)nc2C#N UTQOAIWPJIFJIS-UHFFFAOYSA-N 0.000 description 1
- UKTKIZRBJPLWPJ-UHFFFAOYSA-N CC(C)[n]1nc(C)c(CC2(CCNCC2)C2)c1C2=O Chemical compound CC(C)[n]1nc(C)c(CC2(CCNCC2)C2)c1C2=O UKTKIZRBJPLWPJ-UHFFFAOYSA-N 0.000 description 1
- HXEJBKSDELCRJK-UHFFFAOYSA-N CC(C)[n]1ncc(CC(CC2)(CCN2C(c2cc(OC)nc(-c3cccc(C(O)=O)c3)c2)=O)C2)c1C2=O Chemical compound CC(C)[n]1ncc(CC(CC2)(CCN2C(c2cc(OC)nc(-c3cccc(C(O)=O)c3)c2)=O)C2)c1C2=O HXEJBKSDELCRJK-UHFFFAOYSA-N 0.000 description 1
- ZFXCIWPVPUPDMF-UHFFFAOYSA-N CC(C)[n]1ncc(CC2(CCNCC2)C2)c1C2=O Chemical compound CC(C)[n]1ncc(CC2(CCNCC2)C2)c1C2=O ZFXCIWPVPUPDMF-UHFFFAOYSA-N 0.000 description 1
- QKCMLHYZHDHQFM-UHFFFAOYSA-N CC(C)[n]1ncc(OC2(CCN(Cc3ccccc3)CC2)C2)c1C2=O Chemical compound CC(C)[n]1ncc(OC2(CCN(Cc3ccccc3)CC2)C2)c1C2=O QKCMLHYZHDHQFM-UHFFFAOYSA-N 0.000 description 1
- JPBXJMFKOUSYHN-UHFFFAOYSA-N CC(C)[n]1ncc2c1C=CC(CC1)(CCN1C(OCc1ccccc1)=O)C2 Chemical compound CC(C)[n]1ncc2c1C=CC(CC1)(CCN1C(OCc1ccccc1)=O)C2 JPBXJMFKOUSYHN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38810210P | 2010-09-30 | 2010-09-30 | |
| US61/388,102 | 2010-09-30 | ||
| PCT/IB2011/054119 WO2012042433A1 (en) | 2010-09-30 | 2011-09-20 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013540119A JP2013540119A (ja) | 2013-10-31 |
| JP2013540119A5 JP2013540119A5 (enExample) | 2014-10-16 |
| JP5824055B2 true JP5824055B2 (ja) | 2015-11-25 |
Family
ID=44789556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530829A Active JP5824055B2 (ja) | 2010-09-30 | 2011-09-20 | Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US8859577B2 (enExample) |
| EP (1) | EP2621493B1 (enExample) |
| JP (1) | JP5824055B2 (enExample) |
| CA (1) | CA2811033C (enExample) |
| CY (1) | CY1118016T1 (enExample) |
| DK (1) | DK2621493T3 (enExample) |
| ES (1) | ES2602111T3 (enExample) |
| HR (1) | HRP20161178T1 (enExample) |
| HU (1) | HUE031616T2 (enExample) |
| LT (1) | LT2621493T (enExample) |
| PL (1) | PL2621493T3 (enExample) |
| PT (1) | PT2621493T (enExample) |
| RS (1) | RS55224B1 (enExample) |
| SI (1) | SI2621493T1 (enExample) |
| WO (1) | WO2012042433A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040198483A1 (en) | 2003-04-03 | 2004-10-07 | Amaitis Lee M. | System and method for betting on a subset of participants in an event |
| US8636571B2 (en) | 2004-02-03 | 2014-01-28 | Cantor Index, Llc | System and method for managing select five horseracing bets |
| US9098883B2 (en) | 2004-02-03 | 2015-08-04 | Cantor Index, Llc | Managing bets that select events and participants |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| UA102336C2 (uk) * | 2009-11-10 | 2013-06-25 | Пфайзер Інк. | N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ |
| DK2621493T3 (en) * | 2010-09-30 | 2016-10-24 | Pfizer | N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS |
| CN103189377B (zh) | 2010-10-29 | 2015-02-25 | 辉瑞大药厂 | N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂 |
| EA022375B1 (ru) | 2011-04-22 | 2015-12-30 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ |
| WO2013116359A1 (en) | 2012-01-30 | 2013-08-08 | Cfph, Llc | Event wagering with group and/or in run options |
| US11055967B2 (en) | 2014-03-26 | 2021-07-06 | Cfph, Llc | Event wagering with group and/or in run options |
| US20170178994A1 (en) * | 2015-12-21 | 2017-06-22 | Intel Corporation | Integrated circuit package support structures |
| KR102579876B1 (ko) | 2016-02-22 | 2023-09-18 | 삼성전자주식회사 | 반도체 패키지 |
| CA3058542A1 (en) * | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| EP3713942B8 (en) * | 2017-11-21 | 2023-04-12 | Pfizer Inc. | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| JP7161605B2 (ja) * | 2018-08-31 | 2022-10-26 | ファイザー・インク | Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CN110183456A (zh) * | 2019-07-11 | 2019-08-30 | 河南师范大学 | 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法 |
| CA3163979A1 (en) | 2019-12-10 | 2021-06-17 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| WO2021138540A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| JP2021134211A (ja) * | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| MX2022010811A (es) | 2020-03-27 | 2022-09-27 | Pfizer | Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo. |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN117940422A (zh) | 2021-08-31 | 2024-04-26 | 辉瑞大药厂 | 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸，1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式 |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| IL319392A (en) | 2022-10-18 | 2025-05-01 | Pfizer | Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations |
| CN121002014A (zh) | 2022-12-15 | 2025-11-21 | 加舒布鲁姆生物公司 | 具有glp-1激动剂活性的化合物的盐和固体形式 |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025224648A1 (en) | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| CA2439152C (en) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| WO2003072197A1 (en) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Acc inhibitors |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| JPWO2004092179A1 (ja) | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| WO2005113069A2 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of circumin and analogues as inhibitors of acc2 |
| GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| ATE509023T1 (de) | 2005-07-19 | 2011-05-15 | Merck Sharp & Dohme | Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer |
| CA2617042A1 (en) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| DE102006016566B4 (de) | 2005-09-22 | 2008-06-12 | Beru Ag | Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren |
| CA2629406A1 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirohydantoin aryl cgrp receptor antagonists |
| US8735595B2 (en) | 2006-02-15 | 2014-05-27 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| WO2008065508A1 (en) | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Spiroketone acetyl-coa carboxylase inhibitors |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| WO2008088692A2 (en) * | 2007-01-12 | 2008-07-24 | Merck & Co., Inc. | Spirochromanon derivatives |
| EP2123652A1 (en) | 2007-02-20 | 2009-11-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN101675052A (zh) | 2007-04-12 | 2010-03-17 | 辉瑞大药厂 | 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物 |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| EP2307422B1 (en) * | 2008-07-04 | 2014-03-26 | Msd K.K. | Novel spirochromanone carboxylic acids |
| EP2310015A4 (en) | 2008-07-14 | 2011-10-26 | Cropsolution Inc | ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF |
| CA2778316A1 (en) | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| UA102336C2 (uk) * | 2009-11-10 | 2013-06-25 | Пфайзер Інк. | N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ |
| DK2621493T3 (en) | 2010-09-30 | 2016-10-24 | Pfizer | N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS |
| US20160034775A1 (en) | 2014-08-02 | 2016-02-04 | General Vault, LLC | Methods and apparatus for bounded image data analysis and notification mechanism |
-
2011
- 2011-09-20 DK DK11768163.5T patent/DK2621493T3/en active
- 2011-09-20 HR HRP20161178TT patent/HRP20161178T1/hr unknown
- 2011-09-20 ES ES11768163.5T patent/ES2602111T3/es active Active
- 2011-09-20 CA CA2811033A patent/CA2811033C/en active Active
- 2011-09-20 LT LTEP11768163.5T patent/LT2621493T/lt unknown
- 2011-09-20 WO PCT/IB2011/054119 patent/WO2012042433A1/en not_active Ceased
- 2011-09-20 RS RS20160845A patent/RS55224B1/sr unknown
- 2011-09-20 US US13/876,211 patent/US8859577B2/en active Active
- 2011-09-20 EP EP11768163.5A patent/EP2621493B1/en active Active
- 2011-09-20 PL PL11768163T patent/PL2621493T3/pl unknown
- 2011-09-20 HU HUE11768163A patent/HUE031616T2/hu unknown
- 2011-09-20 JP JP2013530829A patent/JP5824055B2/ja active Active
- 2011-09-20 PT PT117681635T patent/PT2621493T/pt unknown
- 2011-09-20 SI SI201130951A patent/SI2621493T1/sl unknown
-
2014
- 2014-09-19 US US14/491,016 patent/US9145416B2/en active Active
-
2015
- 2015-09-11 US US14/851,572 patent/US20150376185A1/en not_active Abandoned
-
2016
- 2016-08-15 US US15/236,635 patent/US9908883B2/en active Active
- 2016-09-13 CY CY20161100905T patent/CY1118016T1/el unknown
-
2018
- 2018-01-30 US US15/883,109 patent/US10294225B2/en active Active
-
2019
- 2019-04-01 US US16/371,896 patent/US10822335B2/en active Active
-
2020
- 2020-09-28 US US17/034,295 patent/US11673890B2/en active Active
-
2023
- 2023-05-03 US US18/311,715 patent/US20230322777A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK2621493T3 (en) | 2016-10-24 |
| PL2621493T3 (pl) | 2017-01-31 |
| US20130190334A1 (en) | 2013-07-25 |
| US20230322777A1 (en) | 2023-10-12 |
| US9145416B2 (en) | 2015-09-29 |
| US10822335B2 (en) | 2020-11-03 |
| EP2621493B1 (en) | 2016-08-17 |
| US20210047325A1 (en) | 2021-02-18 |
| US20180162858A1 (en) | 2018-06-14 |
| HUE031616T2 (hu) | 2017-07-28 |
| CY1118016T1 (el) | 2017-05-17 |
| RS55224B1 (sr) | 2017-02-28 |
| JP2013540119A (ja) | 2013-10-31 |
| SI2621493T1 (sl) | 2016-10-28 |
| US8859577B2 (en) | 2014-10-14 |
| US20190218218A1 (en) | 2019-07-18 |
| CA2811033C (en) | 2015-10-20 |
| CA2811033A1 (en) | 2012-04-05 |
| PT2621493T (pt) | 2016-11-14 |
| LT2621493T (lt) | 2016-10-25 |
| US20150011470A1 (en) | 2015-01-08 |
| US11673890B2 (en) | 2023-06-13 |
| US10294225B2 (en) | 2019-05-21 |
| ES2602111T3 (es) | 2017-02-17 |
| WO2012042433A1 (en) | 2012-04-05 |
| US9908883B2 (en) | 2018-03-06 |
| EP2621493A1 (en) | 2013-08-07 |
| HRP20161178T1 (hr) | 2016-11-04 |
| US20150376185A1 (en) | 2015-12-31 |
| US20160347752A1 (en) | 2016-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230322777A1 (en) | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | |
| JP5114610B1 (ja) | Ｎ１−ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬 | |
| KR101567659B1 (ko) | 아세틸-CoA 카복실라아제 억제제로 사용하기 위한 피라졸로스피로케톤 유도체 | |
| JP2015057416A (ja) | Ｎ１／Ｎ２−ラクタムアセチル−ＣｏＡカルボキシラーゼ阻害剤 | |
| US20120225900A1 (en) | N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140826 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140826 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150612 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150622 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150908 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151005 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151008 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5824055 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |